Baxter International (NYSE:BAX) Shares Acquired Rep. Robert Bresnahan, Jr.

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of Baxter International Inc. NYSE: BAX. In a filing disclosed on June 09th, the Representative disclosed that they had bought between $1,001 and $15,000 in Baxter International stock on May 15th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Zoom Communications NASDAQ: ZM on 6/25/2025.
• Purchased $1,001 - $15,000 in shares of Coinbase Global NASDAQ: COIN on 6/24/2025.
• Purchased $1,001 - $15,000 in shares of Circle Internet Group NYSE: CRCL on 6/24/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 6/23/2025.
• Sold $1,001 - $15,000 in shares of Chubb NYSE: CB on 6/13/2025.
• Sold $1,001 - $15,000 in shares of Atlassian NASDAQ: TEAM on 6/11/2025.
• Purchased $1,001 - $15,000 in shares of ServiceTitan NASDAQ: TTAN on 6/11/2025.
• Sold $1,001 - $15,000 in shares of Datadog NASDAQ: DDOG on 6/11/2025.
• Sold $1,001 - $15,000 in shares of GitLab NASDAQ: GTLB on 6/11/2025.
• Purchased $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 6/11/2025.

Baxter International Stock Up 1.6%

NYSE BAX traded up $0.46 during trading hours on Friday, hitting $29.23. 4,031,150 shares of the company traded hands, compared to its average volume of 4,666,913. The business's 50-day moving average is $30.02 and its 200-day moving average is $31.17. Baxter International Inc. has a twelve month low of $26.25 and a twelve month high of $40.49. The company has a debt-to-equity ratio of 1.33, a quick ratio of 1.40 and a current ratio of 2.02. The stock has a market capitalization of $15.00 billion, a price-to-earnings ratio of -26.57, a P/E/G ratio of 0.85 and a beta of 0.61.

Baxter International (NYSE:BAX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $0.62 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.14. Baxter International had a positive return on equity of 17.24% and a negative net margin of 4.71%. The company had revenue of $2.63 billion during the quarter, compared to analysts' expectations of $2.59 billion. During the same period last year, the firm posted $0.65 earnings per share. The business's revenue was up 5.4% on a year-over-year basis. Sell-side analysts anticipate that Baxter International Inc. will post 2.48 earnings per share for the current year.

Baxter International Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 1st. Investors of record on Friday, August 29th will be given a dividend of $0.17 per share. The ex-dividend date of this dividend is Friday, August 29th. This represents a $0.68 annualized dividend and a yield of 2.33%. Baxter International's dividend payout ratio (DPR) is presently -61.82%.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Wells Fargo & Company cut their price objective on Baxter International from $36.00 to $33.00 and set an "equal weight" rating for the company in a research report on Friday, May 2nd. Evercore ISI cut their price objective on Baxter International from $44.00 to $42.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Citigroup cut their price objective on Baxter International from $34.00 to $32.00 and set a "neutral" rating for the company in a research report on Wednesday, July 9th. Morgan Stanley lowered their target price on Baxter International from $28.00 to $27.00 and set an "underweight" rating on the stock in a research note on Tuesday, July 15th. Finally, Wall Street Zen upgraded Baxter International from a "hold" rating to a "buy" rating in a research note on Sunday, June 22nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $36.38.

Hedge Funds Weigh In On Baxter International

Several hedge funds and other institutional investors have recently modified their holdings of the business. Horizon Investments LLC grew its position in Baxter International by 5.0% during the 1st quarter. Horizon Investments LLC now owns 7,438 shares of the medical instruments supplier's stock worth $255,000 after acquiring an additional 351 shares during the last quarter. Rothschild Investment LLC grew its position in Baxter International by 3.4% during the 1st quarter. Rothschild Investment LLC now owns 14,479 shares of the medical instruments supplier's stock worth $496,000 after acquiring an additional 481 shares during the last quarter. Archer Investment Corp grew its position in Baxter International by 20.5% during the 1st quarter. Archer Investment Corp now owns 2,935 shares of the medical instruments supplier's stock worth $100,000 after acquiring an additional 500 shares during the last quarter. Home Federal Bank of Tennessee grew its position in Baxter International by 2.5% during the 1st quarter. Home Federal Bank of Tennessee now owns 22,600 shares of the medical instruments supplier's stock worth $774,000 after acquiring an additional 550 shares during the last quarter. Finally, Private Trust Co. NA grew its position in Baxter International by 17.3% during the 1st quarter. Private Trust Co. NA now owns 3,822 shares of the medical instruments supplier's stock worth $131,000 after acquiring an additional 565 shares during the last quarter. Institutional investors own 90.19% of the company's stock.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.